Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLI NASDAQ:CYTR NASDAQ:DYAI NASDAQ:LJPC NASDAQ:TCON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.20-1.6%$1.18$0.72▼$6.45$11.81M0.22401,952 shs250,218 shsCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsDYAIDyadic International$0.99-1.1%$1.00$0.91▼$2.20$29.77M0.8854,847 shs19,104 shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsTCONTRACON Pharmaceuticals$0.03$0.04$0.00▼$14.75$110K1.37120,908 shs23,886 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics0.00%+5.26%+1.69%+57.40%-77.21%CYTRLadRx0.00%0.00%0.00%0.00%0.00%DYAIDyadic International0.00%+6.25%+4.77%-20.10%-27.80%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%TCONTRACON Pharmaceuticals0.00%0.00%0.00%0.00%-95.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics1.4365 of 5 stars0.02.00.04.72.70.80.6CYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/ADYAIDyadic International2.8697 of 5 stars3.55.00.00.02.21.70.0LJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ATCONTRACON PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 0.00N/AN/AN/ACYTRLadRx 0.00N/AN/AN/ADYAIDyadic International 3.00Buy$6.00506.55% UpsideLJPCLa Jolla Pharmaceutical 0.00N/AN/AN/ATCONTRACON Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ACYTRLadRxN/AN/AN/AN/AN/AN/ADYAIDyadic International$3.49M8.53N/AN/A$0.08 per share12.37LJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00TCONTRACON Pharmaceuticals$12.05M0.01$1.61 per share0.02($0.37) per share-0.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)CYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/ADYAIDyadic International-$5.81M-$0.20N/AN/AN/A-163.94%-233.69%-59.37%8/12/2025 (Estimated)LJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/ATCONTRACON Pharmaceuticals-$3.59M$3.730.01∞N/AN/A-237.65%57.29%N/ALatest TCON, CYTR, LJPC, BCLI, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/14/2025Q1 2025DYAIDyadic InternationalN/A-$0.07N/A-$0.07N/A$0.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACYTRLadRxN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/ATCONTRACON PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.210.21CYTRLadRxN/AN/AN/ADYAIDyadic International5.403.983.98LJPCLa Jolla PharmaceuticalN/A4.023.52TCONTRACON PharmaceuticalsN/A0.660.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CYTRLadRxN/ADYAIDyadic International27.95%LJPCLa Jolla Pharmaceutical97.06%TCONTRACON Pharmaceuticals11.61%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%CYTRLadRxN/ADYAIDyadic International29.50%LJPCLa Jolla Pharmaceutical36.30%TCONTRACON Pharmaceuticals5.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics409.84 million8.74 millionOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableDYAIDyadic International730.09 million21.21 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionableTCONTRACON Pharmaceuticals203.41 million3.23 millionNo DataTCON, CYTR, LJPC, BCLI, and DYAI HeadlinesRecent News About These CompaniesTRACON Pharma (OTC:TCON) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTRACON Pharmaceuticals Announces it Will Wind Down OperationsJuly 30, 2024 | globenewswire.comTRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma PatientsJune 11, 2024 | globenewswire.comTRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock Price Settled at $1.49: What’s Resulting?May 27, 2024 | bovnews.comBTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call TranscriptMay 15, 2024 | msn.comQ1 2024 TRACON Pharmaceuticals Inc Earnings CallMay 15, 2024 | finance.yahoo.comTRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comTCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024May 14, 2024 | investorplace.comTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | finance.yahoo.comTracon: Q1 Earnings SnapshotMay 14, 2024 | timesunion.comTTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | globenewswire.comTRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024May 7, 2024 | globenewswire.comTRACON Pharmaceuticals IncApril 26, 2024 | money.usnews.comBuy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation UpdateApril 10, 2024 | markets.businessinsider.comTRACON announces 1-for-20 reverse stock splitApril 10, 2024 | uk.investing.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 10, 2024 | investorplace.comShares of Tracon Pharmaceuticals Tumble 22% on Reverse SplitApril 8, 2024 | marketwatch.comTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock SplitApril 8, 2024 | finanznachrichten.deTRACON Pharmaceuticals Announces Reverse Stock SplitApril 8, 2024 | globenewswire.comBuy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial OutlookApril 4, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCON, CYTR, LJPC, BCLI, and DYAI Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$1.20 -0.02 (-1.64%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.25%) As of 07/11/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.LadRx NASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Dyadic International NASDAQ:DYAI$0.99 -0.01 (-1.07%) Closing price 07/11/2025 03:49 PM EasternExtended Trading$0.99 +0.00 (+0.28%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.La Jolla Pharmaceutical NASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.TRACON Pharmaceuticals NASDAQ:TCONTRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.